Sydney Antibody Therapeutics
Conference
7th & 8th May 2025
Join us for two days featuring the experts showcasing the latest in antibody research and technology
Speakers
Meet our Speakers
President of the Antibody Society (2022-2023), Professor of Molecular Immunology and Director of Translational Immunology, University of Southampton
New Zealand Prime Minister's Chief Science Advisor, Professor of Biochemistry, University of Auckland
local & international speakers
Georgina Clark
The ANZAC Research Institute
Peter Hudson
Avipep Therapeutics
Mark Hogarth
Burnet Institute
Michael Wheatcroft
Telix Pharmaceuticals
Patrick Schlegel
Biosceptre
Sheryl Van Nunen
Northern Beaches Hospital
Andrew Scott
Olivia Newton-John Cancer Research Institute
Henry Maun
Genentech
Daniel Scott
The Florey Institute and LASEREDD Therapeutics
Mihriban Tuna
Immutrin and Cambridge Innovation Capital
Rowena Bull
University of New South Wales
Stephen Mahler
Aegros
Anthony Doyle
Teva Pharmaceuticals
Louis Fabri
CSL
Mark Liddament
CSL
Nicole Smith
University of Western Australia
Imad Ajjawi
Absci
Final list to be announced at the end of March
Secure your spot for Sydney Antibody Therapeutics 2025
Venue
CONFERENCE
Join us at the N’Galawa Terrace in the Taronga Centre at Taronga Zoo
ACCOMMODATION
Stay at the zoo
Enjoy an overnight stay at Taronga Zoo Sydney for a truly unique and immersive experience amongst the wild.
Program
Day 1
7th May 2025
Day 2
8th May 2025
KEYNOTE
Streamlining development of next-gen t-cell engagers
Carl Hansen
SESSION ONE – DISCOVERY
Mapping antibody epitopes in hepatitis C and Covid-19 patients
Rowena Bull
Lentiviral-driven directed evolution of optimised GPCRs for antibody discovery
Daniel Scott
SESSION TWO – ONCOLOGY (I)
Antibody targeting of tumour cells and microenvironment
Andrew Scott
Bispecific antibodies in cancer immunotherapy – could they be the next big breakthrough?
Mihriban Tuna
SESSION THREE – DEVELOPMENT (I)
Project turbo: An accelerated development approach to early clinical development
Louis Fabri
Production of an anti-SARS-CoV-2 globulin from COVID-19 convalescent plasma by HaemaFrac® technology
Stephen Mahler
SESSION FOUR – DEVELOPMENT (II)
CSL's Innovative Clinical-Stage Antibody Pipeline: Leveraging external innovation and collaboration to improve patient outcomes
Mark Liddament
Harnessing the therapeutic potential of cytokines: reducing toxicity by specifically directing activity to target cell population by antibody-mediated delivery of attenuated cytokine
Anthony Doyle
KEYNOTE
Antibodies and antibody mimics
Greg Winter (Virtual)
SESSION FOUR – NOVEL TARGETS AND TECHNOLOGIES (I)
KEYNOTE
The Twist synthetic biology platform
Maxwell Stefan
Antibodies against alpha-galactose in allergy and xenotransplantation
Sheryl van Nunen
Stellabody® modification transforms effector function of therapeutic mAbs and Fc fusions
Bruce Wines
SESSION FIVE – NOVEL TARGETS AND TECHNOLOGIES (II)
Inhibition of tetrameric β-tryptase for severe asthma by mono- and bivalent antibodies with distinct allosteric mechanisms of action
Henry Maun
Anti-CD300f antibody drug conjugate facilitates a targeted conditioning regimen for allogeneic stem cell transplantation in AML
Georgina Clark
Antibody design using generative AI
Imad Ajjawi
SESSION SIX – ONCOLOGY (II)
Engineered Avibodies (enhanced Diabodies) precisely loaded with novel ADC payloads that surpass IgG-ADCs in cancer therapy
Peter Hudson
How antibodies can pave the way for CAR T cell therapy
Patrick Schlegel
Antibody-directed radiation (Theranostics)
Michael Wheatcroft
Sponsors
Organisers
Platinum Sponsors
Coffee Station Sponsor
Gold Sponsors
Silver Sponsors
Sponsors
Want to be a Sponsor?
Contact us with the form below to learn more about sponsorship opportunities.
Contact Us
sponsorship applications close friday 21st April
Take this unique opportunity to gain brand awareness and visibility within the Australian and International Antibody Therapeutic community